Koninklijke Philips N.V. (RYLPF)
OTC Markets OTCPK
Price as at 1 Oct 2026, 00:52 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Koninklijke Philips N.V. trades at $25.05. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Koninklijke Philips N.V.
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its RYLPF data?
Fundamentals for RYLPF come from company filings and exchange data, as listed on OTC Markets OTCPK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:52 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RYLPF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.